{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.01","upperLimit":"8.4","value":"5.8"},{"groupId":"OG001","lowerLimit":"4.2","upperLimit":"11.2","value":"8.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"Duration of response is defined as the time from the date of first documented response (which is subsequently confirmed) until date of documented progression per RECIST 1.1, as assessed by investgator, or death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Final Analysis with DCO on 06May2024","id":"OG000","title":"TNBC Cohort"},{"description":"Final Analysis with DCO on 27Nov2024","id":"OG001","title":"NSCLC Cohort"}],"paramType":"MEDIAN","populationDescription":"FAS: Enrolled participants who have received at least one dose of treatment. The analysis for DOR assessed by investigator was based on the responders in the FAS of each cohort.","reportingStatus":"POSTED","timeFrame":"TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.","title":"Duration of Response (DoR), Assessed by Investigator","type":"SECONDARY","unitOfMeasure":"months"}